44 Pageviews Read Stories
Causes: Adult Education, Education
Mission: Vpi strives to be the premier educator in the field of vascular medicine and intervention. Vpi's team of specialists in vascular medicine, interventional cardiology, interventional radiology, and vascular surgery is driven by the passion for advancing the field of vascular medicine with a spirit of collegiality. Vpi's mission is to synergize the collective talents of these recognized experts to promote the awareness and innovative therapeutic options for vascular disease. Vpi pledges to maintain the highest scientific integrity and to promote research, education and pioneering therapy to improve the care of patients with peripheral vascular disease (pvd) worldwide.
Programs: Education:the organization sponsors vascular interventional advances ("viva"), the global education course for vascular medicine and intervention. Viva is conducted annually in las vegas, nevada and on a smaller scale with other nonprofit organizations in a collaborative role both domestic and worldwide. (continued on schedule o)viva is sponsored by vpi and contracts with an accredited continuing medical education (cme) provider to approve credits for physician attendees and various other accrediting bodies to approve credits for nurses and other healthcare professionals. Viva furthers vpi's exempt purpose as both an accredited continuing medical education program, and a forum for promoting the latest research findings and technology in the field of vascular medicine and intervention. In 2015, viva added a two-day program, the veins (venous endovascular interventional strategies), focused exclusively on treating patients with venous disease. This course was held the two days preceding the viva 15 and 16 programs. This course continued in 2017 and is planned for 2018. Vpi has supported a multidisciplinary fellowship for several years. In the past three years, additional opportunities for training fellows have been incorporated into the annual viva conference. Viva recently partnered with the american heart association to provide research grants for fellows. Viva is funded primarily through unrestricted educational grants from commercial supporters in accordance with standards of the american council for continuing medical education (accme). Viva also generates funds through registration and tuition payments from the conference attendees. Vpi strives to be the premier educator in the field of vascular medicine and intervention and to associate the name "viva" with cutting edge and state-of-the-art programs that serve the public good by promoting advances in treatment of peripheral vascular disease. Research:vpi sponsors research and pioneering therapy in the field of vascular medicine. Vpi receives grants from industry as well as contributions from private individuals in support of pvd research. Vpi has managed several fda approved studies related to pvd treatment. These trials follow good clinical practice (gcp) protocols and require strict institutional review board (irb) approval at each site. Beginning in 2012, vpi expanded its international educational opportunities by collaborating with international organizations to provide state of the art learning modalities and cutting-edge programs in countries such as brazil, germany, great britain, israel and china. In 2014, vpi launched a virtual viva application that made it possible for international and military physicians to participate in the annual viva conference remotely. In 2015, viva offered complimentary access to educational content through the virtual viva app to international physicians who attended the program in germany as well as all active military physicians. Advocacy:as part of viva's strategic plan, patient care advocacy programs, focused on advancing the field of vascular disease care, are planned to include thought leaders and government agencies, including the fda and cms. The first program was held april 2016 and focused on the global management of critical limb ischemia, one of the most challenging patient disorders. The second "vascular disease forum" is planned for 2018, focusing on treatment and management of carotid artery disease. During the year, total of approximately 1,695 people were served for viva conference and 341 people were served for veins (two day program).